Universal HealthWatch in $12 million medical technology deal with Russia
This article was originally published in Clinica
Under a one-year $12 million contract, privately-owned Universal HealthWatch (US) will provide medical technology to Russia. Programmes include provision of diagnostics for communicable diseases; the transfer of manufacturing technology for diagnostics to Russia over five years; an evaluation and exchange of technology between the two countries; conducting seminars on surgical procedures; and consultancy services for GMP manufacture.
You may also be interested in...
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.